Evidence for covalent binding of adriamycin to rat liver microsomal proteins

Pietro Ghezzi, Maria Grazia Donelli, Claudio Pantarotto, Terenzio Facchinetti, Silvio Garattini

Research output: Contribution to journalArticlepeer-review


Adriamycin (NSC-123, 127) is an anticancer drug of the anthracycline type widely used in the clinical practice for the treatment of different malignancies (1). Intercalation with DNA has been suggested as having a role in the mechanism of action of this drug (2, 3, 4). Recently, reports by Sinha (5) and Lucacchini et al. (6) suggested a covalent interaction of Adriamycin (AM) with DNA and proteins. These studies, however, were not conclusive since they were carried out by spectrophotometric and Chromatographie procedures. In the present study a covalent interaction between AM and microsomal proteins was demonstrated in a more "classical" covalent binding study with the 14C-labelled compound.

Original languageEnglish
Pages (from-to)175-177
Number of pages3
JournalBiochemical Pharmacology
Issue number2
Publication statusPublished - Jan 15 1981

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Evidence for covalent binding of adriamycin to rat liver microsomal proteins'. Together they form a unique fingerprint.

Cite this